Anavex Life Sciences to Announce Fiscal 2021 3rd Quarter Financial Results on Thurs., Aug. 12, 2021

Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021

Anavex Life Sciences Announces ANAVEX®2-73 Significantly Prevented Aβ (Abeta)-induced Deficits

Anavex Life Sciences Announces ANAVEX®2-73 Improved both Primary Cognitive and Second MDS-UPDRS

Anavex Life Sciences Announces Closing of $50 Million Registered Direct Offering

Anavex Life Sciences Announces $50 Million Registered Direct Offering

Anavex Life Sciences Announces ANAVEX®2-73 Biomarker Correlated with Efficacy Endpoint in Trial

Anavex Life Sciences Reports the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B)

Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73

Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73

Anavex Life Sciences Announces Appointment of Ms. Jiong Ma, PhD to Board of Directors